Barclays raised the firm’s price target on Alvotech to $20 from $17 and keeps an Overweight rating on the shares. The company’s 2024 guidance is materially above on both revenue and EBITDA, but more importantly the 2025 outlook sees the trend continuing, further indicating its strong global biosimilar opportunity, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALVO: